Eloxx Pharmaceuticals Inc.
08/26/2021 | Press release | Archived content
Correspondence (SEC Filing - CORRESP)
Eloxx Pharmaceuticals, Inc.
480 Arsenal Way
Watertown, MA 02472
August 26, 2021
Via EDGAR Transmission
Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
| Re: | ELOXX PHARMACEUTICALS, INC. |
Registration Statement on Form S-3 (Registration No. 333-258994)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-258994) (the "Registration Statement") of Eloxx Pharmaceuticals, Inc. (the "Company"). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on August 30, 2021, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Please contact Wesley C. Holmes of Latham & Watkins LLP, counsel to the Company, at (617) 948-6027, or in his absence, Peter Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
| Very truly yours, | |||
| ELOXX PHARMACEUTICALS, INC. | |||
| By: | /s/ Sumit Aggarwal | ||
| Name: | Sumit Aggarwal | ||
| Title: | Chief Executive Officer |
| cc: | Daniel E. Geffken, Eloxx Pharmaceuticals, Inc. |
| Peter N. Handrinos, Latham & Watkins LLP | |
| Wesley C. Holmes, Latham & Watkins LLP |